Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.

Immunotherapy·2026

Same author

Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.

JTO clinical and research reports·2026

Same author

The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

18F-FDG PET/CT for predicting major pathological response to neoadjuvant therapy in non-small cell lung cancer: a meta-analysis.

Frontiers in oncology·2026

Same author

Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine·2026

Same author

Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity.

Med (New York, N.Y.)·2026

Search research articles

Related Experiment Video

Updated: Jan 10, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Tumor-Agnostic Drug Development.

Michael Offin¹, Dazhi Liu¹, Alexander Drilon¹

¹From the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting

|September 21, 2018

Summary

This summary is machine-generated.

Targeted cancer therapies and next-generation sequencing are revolutionizing oncology. Tumor-agnostic basket trials improve access to these treatments for rare molecular alterations.

More Related Videos

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Related Experiment Videos

Last Updated: Jan 10, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Area of Science:

Oncology
Genomics
Clinical Trial Design

Background:

Molecularly targeted therapies have transformed cancer treatment.
Next-generation sequencing (NGS) increases identification of specific cancer alterations.
Rare molecular alterations present challenges for traditional drug development.

Purpose of the Study:

To review genomically enriched trial strategies.
To discuss the impact of these trials on drug development and approval.
To highlight the role of basket trials in studying targeted therapies.

Main Methods:

Review of key aspects of tumor-agnostic trial designs.
Analysis of the impact on oncologic drug development.
Examination of patient access to novel therapies.

Main Results:

Genomically enriched trials accelerate the study of targeted therapies.
Basket trials facilitate investigation of treatments across diverse tumor types.
These strategies increase patient access to precision oncology drugs.

Conclusions:

Tumor-agnostic trials, like basket trials, are crucial for developing targeted cancer therapies.
These innovative designs improve drug approval pathways.
They enhance patient access to treatments for rare molecular alterations.